Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from colorectal and appendiceal cancer: five-years of experience

Main Article Content

Giulia Montori *
Paola Fugazzola
Marco Ceresoli
Andrea Gianatti
Vincenzo Gatti
Gian Carlo Taddei
Federico Coccolini
Roberto Manfredi
Luca Ansaloni
(*) Corresponding Author:
Giulia Montori |


An increasing promising evidence support the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinosis from colorectal cancer (CRC) and appendiceal cancer (AC). In our institute 18 patients with CRC and 4 patients with AC undergone to CRS and HIPEC were retrospectively analyzed from 2011 to 2016. Patients and tumor characteristics were analyzed. Overall survival and disease free survival were analyzed with Kaplan-Meier curves and log-rank testing. Median disease free survival (DFS) is 20.5 and 31.4 months in CRC and AC respectively (P=0.76). Instead mean overall survival is 37.8 and 44.6 months in CRC and AC group respectively (P=0.46). Primary CRC have an improved DFS compared patients with relapse tumor (45.2 versus 19.4 months) (P=0.037). Comparing with conventional chemotherapy regimens CRS and HIPEC from CRC and AC may obtain a better disease control particularly when a complete cytoreduction is achieved. The combined treatment can have a potential curative intent.

Downloads month by month


Download data is not yet available.

Article Details

Author Biography

Giulia Montori, Department of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo

emergency and trauma dept

Most read articles by the same author(s)